“We're going to be able to treat many more patients who suffer from BPH/LUTS with these less invasive options,” says Dean S. Elterman, MD, MSc, FRCSC.
In this video, Dean S. Elterman, MD, MSc, FRCSC, shares the take-home message from the publication, “A scoping review of office-based prostatic stents: past, present, and future of true minimally invasive treatment of benign prostatic hyperplasia,” for which he served as the senior author. Elterman is a urologist at University Urology Associates and a faculty member in the University of Toronto's division of urology in Ontario, Canada.
I think the overall take-home message is that office-based procedures for BPH are certainly here to stay. We have had things like Rezum and UroLift on the market, iTind, and exciting that the Optilume BPH just got FDA approved, and all these new stents are going to come out. We've learned from the mistakes and the challenges of the old stents from the 1990s. I'm hopeful that the new knowledge and the application to these new stents is going to allow them to be more successfully utilized with lower complication rates, and therefore we're going to be able to treat many more patients, many more men who suffer from BPH/LUTS with these less invasive options. Of course, if stents don't work in a particular man, they'll be easy to remove, and they can move on to another type of surgery. It really is going to be able to open up our therapy options for men suffering from BPH/LUTS.
This transcription has been edited for clarity.